A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus
- PMID: 2070568
- DOI: 10.1016/0090-1229(91)90065-i
A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus
Abstract
To determine whether there is an intrinsic defect in T cells from patients with systemic lupus erythematosus (SLE), we studied signal transduction systems, assaying the total protein kinase C (PKC) levels and the phorbol myristate acetate (PMA)-induced activation of PKC in PHA-treated T cells. T cells from SLE patients showed a decrease in proliferation in response to PMA, but not to PHA, thereby suggesting the existence of an intrinsic abnormality in the PKC-mediated activation pathway. Total PKC activity in the T cells from SLE patients was significantly decreased. Although stimulation with PMA induced a translocation of PKC from the cytosol to the particulate fraction, translocated PKC activity after 2 nM PMA treatment was decreased in the SLE T cells. Furthermore, PMA-induced phosphorylation of 80-kDa substrates was also decreased in SLE T cells. These results suggest that there is a reduced PKC activity and an impaired PKC activation in response to PMA in the SLE T cells, a finding which may explain, if partially, the defect in T cell activation in patients with SLE.
Similar articles
-
Phorbol myristate acetate (PMA) reverses inhibition of interleukin-2 production by T lymphocytes of patients with systemic lupus erythematosus.Med Interne. 1988 Jan-Mar;26(1):67-73. Med Interne. 1988. PMID: 3261032
-
Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus.Lupus. 1997;6(1):48-56. doi: 10.1177/096120339700600107. Lupus. 1997. PMID: 9116719
-
Impaired T-cell activation in patients with systemic lupus erythematosus.J Clin Immunol. 1989 Nov;9(6):469-76. doi: 10.1007/BF00918016. J Clin Immunol. 1989. PMID: 2517125
-
Regulation of protein kinase C isoform proteins in phorbol ester-stimulated Jurkat T lymphoma cells.J Immunol. 1993 Mar 1;150(5):1746-54. J Immunol. 1993. PMID: 8436813
-
Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate.Arthritis Rheum. 1988 Jul;31(7):826-33. doi: 10.1002/art.1780310702. Arthritis Rheum. 1988. PMID: 3260781
Cited by
-
Therapeutic potential of protein kinase C inhibitors.Agents Actions. 1993 Jan;38(1-2):135-47. doi: 10.1007/BF02027225. Agents Actions. 1993. PMID: 8480534 Review.
-
PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells.J Immunol. 2008 Sep 1;181(5):3658-64. doi: 10.4049/jimmunol.181.5.3658. J Immunol. 2008. PMID: 18714041 Free PMC article.
-
The pathology of T cells in systemic lupus erythematosus.J Immunol Res. 2014;2014:419029. doi: 10.1155/2014/419029. Epub 2014 Apr 23. J Immunol Res. 2014. PMID: 24864268 Free PMC article. Review.
-
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.Ann Rheum Dis. 2001 Apr;60(4):380-4. doi: 10.1136/ard.60.4.380. Ann Rheum Dis. 2001. PMID: 11247869 Free PMC article.
-
The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus.Arthritis Res Ther. 2011;13(5):245. doi: 10.1186/ar3484. Epub 2011 Oct 31. Arthritis Res Ther. 2011. PMID: 22044622 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical